Krka Expands NSAID Portfolio With Launch Of Robexera® Injectable
3 days ago 
112 views
Krka UK has announced the launch of Robexera® 20 mg/ml injectable solution, the first generic robenacoxib injectable available in the UK. Robexera® gives clinicians access to a more affordable, highly COX-2 selective injectable non-steroidal anti-inflammatory drug (NSAID), indicated for the targeted control of perioperative pain and inflammation in cats and dogs.
The injection format delivers the same benefits seen across the Robexera® range, including fast onset of action within an hour with a 24-hour duration, while its high COX-2 selectivity reduces wider systemic impact.1
In cats, the perioperative case is particularly strong. Research has shown robenacoxib to have the best proven safety profile in cats of all NSAIDs.1 It is also highly effective in reducing post-operative pain, with evidence of superior efficacy to meloxicam,2 and a proven anaesthetic-sparing effect during feline surgery.3
Current pain management guidelines emphasise a proactive approach to acute surgical pain, recognising that poorly controlled nociception can trigger central sensitisation and complicate recovery. Renzo Di Florio, Krka’s Technical Veterinary Adviser, said, “Once central sensitisation takes hold, you're managing a much harder problem. Pre-emptive protocols exist to prevent that - and having an injectable robenacoxib that is highly COX-2 selective, with proven efficacy, gives veterinary teams an option they can use confidently.”
Will Ridgway, Head of Animal Health at Krka UK, said, “Practices want product assurance and commercial value. As a bioequivalent to the originator product,4 Robexera® injectable delivers both. That is reflected in our recent customer survey,5 which highlights strong confidence in both Krka products and our clear pricing approach, at a time when value matters more than ever.”
Krka is one of Europe's largest generic pharmaceutical manufacturers, with an established and growing presence in the UK veterinary market. The Robexera® range forms part of a broader portfolio developed to offer practices clinically proven, cost-effective pharmaceuticals for companion and farm animal care.
For more information, view the SPC or contact KRKA UK by emailing [email protected].
Further developments in the Robexera® portfolio are expected later this year.
References
- Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052.
- Kamata, M. et al. (2012) Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. The Veterinary Journal vol. 193, Issue 1, July 2012, Pages 114-115. DOI: 10.1016/j.tvjl.2011.11.026
- Rosa, L. et al (2024) Effects of Robenacoxib on the minimum alveolar concentration of isoflurane in domestic felines. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 76(6) DOI: 10.1590/1678-4162-13111
- Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB) Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on https://www.vmd.defra.gov.uk/productinformationdatabase/files/UKPAR_Documents/ UKPAR_3147525.PDF
- Mo Gannon and Associates Market Research - Krka Customer Survey – August 2025.
More from Companion Consultancy
- AHPR reinforces leadership role in legislative reform following Defra consultation on VSA
- BreathEazy launches new podcast on equine respiratory health and performance
- Krka adds Prazemo® spot-on cat wormer to parasiticide portfolio
- Dignipets announces new partnership with Association of Pet Bereavement Counsellors
- A new chapter for the BSAVA as CEO transition announced
